Member Spotlight: GeneFab
Philip Lee, Ph.D. (CEO) on Bridging Design and Delivery
Biocom California’s LifeLines newsletter features GeneFab CEO Philip Lee, PhD, on why design and manufacturing need to be planned together.
In this month’s LifeLines member spotlight, Biocom California interviews Dr. Lee on how GeneFab was built to close the gap between early-stage therapeutic design and commercial manufacturability in cell and gene therapy.
Topics covered
An integrated model. GeneFab pairs synthetic biology design expertise with GMP manufacturing, reducing the timeline and quality risk of handoffs between design, process and analytical development, and GMP.
Manufacturing strategy from day one. Dr. Lee explains why investors now diligence manufacturing early, why a therapy’s sequence design affects how it can be produced, and why teams benefit from a CMC partner that can start early and scale with the program.
From bench to IND. His advice for early-stage teams: define success criteria in detail up front, and understand product-specific potency assays early, since they can become the rate-limiting step.
In vivo modalities. He describes the safety and impurity demands of in vivo vectors, and GeneFab’s in vivo platform that combines targeting, expression, and a process designed to minimize impurities and tech transfer time.
The Bay Area advantage and what’s next. Proximity to local biotechs speeds problem-solving and tech transfer, and Dr. Lee shares his outlook on in vivo therapies and AI-enabled biomanufacturing.
Asked how a modern CDMO should work, Dr. Lee points to the shift in therapeutics from “finding” to “building.” His advice to newcomers to the industry is to maintain a learning mindset.
Read the full interview on Biocom ↗
Related: In vivo lentiviral vector manufacturing · Genetic Design · Rapid Technology Transfer
About GeneFab
GeneFab is a contract development and manufacturing organization (CDMO) founded in 2023 to advance cGMP-compliant cell and gene therapies. The company partners with innovators to design, develop, and manufacture transformative therapies through an integrated technology platform spanning synthetic biology, in vivo vectors, and autologous and allogeneic ex vivo cell therapy production, from its Bay Area, California facilities.